Search Results for: Immunosuppressants

July 6, 2019July 6, 2019

TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma.

Melanoma Literature

Publication date: Jul 01, 2019 To investigate an association between tumor necrosis factors-alpha (TNFα) inhibitors or other immunosuppressants and the development of uveal and cutaneous melanoma. We performed a retrospective ... Read more

July 2, 2019July 2, 2019

Immunosuppressants in the Development of Melanoma

Melanoma Media

Publication date: Jul 01, 2019 Dr. Lauren A. Dalvin, Director of the Ocular Oncology Service at Mayo Clinic in Rochester, MN, reviews her article appearing in the July 2019 issue ... Read more

February 21, 2018February 21, 2018

Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis.

Multiple Sclerosis Literature

Publication date: Feb 19, 2018 Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an immune mediated pathogenesis. Several therapies that suppress or modulate diverse ... Read more

December 6, 2019December 6, 2019

FDA Approves First Generics for Common Multiple Sclerosis Drug

Multiple Sclerosis News

Publication date: Dec 06, 2019 These are the first generics of the drug, which treats relapsing forms of multiple sclerosis (MS) in adult patients. The approvals were granted to HEC ... Read more

December 2, 2019December 2, 2019

Year in Review: Multiple Sclerosis

Multiple Sclerosis News

Publication date: Dec 02, 2019 Two other MS drugs earned OKs this year, the first being siponimod (Mayzent) for adult patients with relapsing forms of MS, including clinically isolated syndrome, ... Read more

November 30, 2019November 30, 2019

Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: from basic science to clinical practice.

Precision Medicine Literature

Publication date: Nov 28, 2019 Inflammatory bowel diseases (IBD) -ulcerative colitis and Crohn’s disease- are commonly treated with biologic drugs. However, only approximately two thirds have an initial response to ... Read more

November 27, 2019November 27, 2019

How Can We Apply Guidelines in the Rapidly Changing MS Treatment Landscape?

Multiple Sclerosis Media

Publication date: Nov 26, 2019 Management of multiple sclerosis (MS) occurs in a rapidly changing environment in which decisions must be made using the latest available data and insights. This ... Read more

November 27, 2019November 27, 2019

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Multiple Sclerosis News

Publication date: Nov 26, 2019 The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients ... Read more

November 16, 2019November 16, 2019

Anti-TNF, a magic bullet in cancer immunotherapy?

Melanoma Literature

Publication date: Nov 14, 2019 Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events ... Read more

November 13, 2019November 13, 2019

MENACTRIMS guidelines for multiple sclerosis updated

Multiple Sclerosis News

Publication date: Nov 13, 2019 (HealthDay)-In a revised 2019 guideline, published in the January 2020 issue of Multiple Sclerosis and Related Disorders, updated recommendations from the Middle East North Africa ... Read more